Previous close | 0.5500 |
Open | 0.5500 |
Bid | 0.0000 |
Ask | 1.2500 |
Strike | 25.00 |
Expiry date | 2024-05-17 |
Day's range | 0.5500 - 0.5500 |
Contract range | N/A |
Volume | |
Open interest | 7 |
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported finan
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, M
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, MacroGenics ( NASDAQ:MGNX...